Mobile website
Expert Forum
CAR-T cell precise therapy for hematologic malignancies: four key breakthroughs, existing problems and solutions
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] Hematologic malignancies are a severe threat to human health. CAR-T cell therapy, as a highly effective treatment for hematologic malignancies, has become one of the fastest developing cancer immunotherapies in recent years. To obtain highly effective and low-toxicity CAR-T cells, through continuous development and exploration, CAR-T cell therapy has achieved a series of significant breakthroughs in treating hematologic malignancies, including humanized CAR-T cell technology, dual-target and multitarget CAR-T cell technology, universal CAR-T cell technology, and CAR-T cell combination strategy technology. Humanized CAR-T cell technology reduces immunogenicity through humanized modification. Dual-target and multi-target CAR-T cell technology recognizes two or more tumor antigens, minimizes antigen escape and enhance efficacy. Universal CAR-T cell technology solves problems such as high cost and accessibility issues. The CAR-T cell combination strategy technology effectively deals with CAR-T recurrence and enhances efficacy and safety by combining different treatment methods. Although CAR-T cell therapy has achieved significant breakthroughs in the treatment of hematologic malignancies, it still faces challenges such as drug resistance, antigen escape, cytotoxicity, and posttreatment recurrence. This review presents the significant breakthroughs, existing problems, and solutions for CAR-T cell precise therapy for hematological malignancies.
Keywords:
Project Supported:
Clc Number:
